Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.2MCash on Hand
9.8mo Cash Runway
Follow KALA by emailGet an email when KALA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KALA, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Listing On November 13, 2026, the Nasdaq Hearings Panel granted KALA BIO's request to continue its listing, conditioned on a closing bid price of at least $1.00 for ten consecutive business days by November 30, 2026, and on maintaining that price through February 23, 2027. Form 8-K · SEC filing
Nov 12, 2026 ·
Shareholder vote KALA BIO will effect a 1-for-30 reverse stock split, effective 4:05 p.m. on November 13, 2026, with split-adjusted trading on Nasdaq starting November 16, 2026. Shares outstanding drop from 19,339,786 to about 644,659, and the new CUSIP is 483119400. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Earnings Preliminary unaudited Q3 2026 net loss of approximately $0.8 million versus $7.6 million a year earlier. Nine-month net loss of approximately $4.0 million versus $27.7 million. Cash and short-term investments of approximately $7.0 million, with no debt. Form 10-Q expected on or about November 16, 2026. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Shareholder vote Shareholders at the annual meeting elected Yonatan Colman and Brendan Purdy as Class III directors through 2029, approved executive compensation on an advisory basis, ratified HTL International, LLC as auditor for 2026, and approved a reverse stock split ratio between 1-for-2 and 1-for-300 at the board's discretion. Form 8-K · SEC filing
Sep 24, 2026 ·
Shareholder vote KALA BIO will hold its 2026 virtual annual meeting on November 3, 2026, where stockholders will vote on electing two Class III directors, a non-binding say-on-pay vote, ratifying HTL International as auditor, and a reverse stock split at a ratio between 1-for-2 and 1-for-300. Form DEF 14A · SEC filing
Sep 10, 2026 ·
Deal Kala entered a five-year Exclusive Distribution and Reseller Agreement with Virotek dated September 3, 2026 for a genetic testing and screening program for ophthalmology in the US. Exclusivity converts to non-exclusive if a milestone set for September 3, 2027 is missed, subject to a 30-day cure period. Form 8-K · SEC filing
Sep 9, 2026 ·
Shareholder vote KALA set November 3, 2026 as the date of its next annual stockholder meeting. Stockholder proposals under Rule 14a-8 and director nominations must be received by September 19, 2026. Form 8-K · SEC filing
Aug 28, 2026 ·
Listing Received a Nasdaq Staff Determination Letter on August 27, 2026, citing a closing bid below $1.00 for 30 consecutive business days and no compliance period due to a 1-for-50 reverse split on May 11, 2026. The company intends to request a Panel hearing, which stays any delisting action. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
KALA holds $7.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.2M/quarter from operations,
an estimated runway of 9.8 months at that rate (BioRadar estimate, not company guidance).
Share count 19,339,786 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full KALA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KALA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.